Valuation: Evaxion A/S

Market Cap 25.6M 22.86M 21.26M 19.34M 36.51M 2.48B 36.65M 256M 100M 1.26B 96.13M 94.04M 4.05B P/E 2026 *
-76.8x
P/E 2027 * -205x
Enterprise Value 25.6M 22.86M 21.26M 19.34M 36.51M 2.48B 36.65M 256M 100M 1.26B 96.13M 94.04M 4.05B EV / Sales 2026 *
-
EV / Sales 2027 * 5.48x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.66%
1 week-4.06%
Current month-6.40%
1 month-1.92%
3 months-3.15%
6 months-24.01%
Current year-35.64%
1 week 3.02
Extreme 3.02
3.25
1 month 3
Extreme 3
3.35
Current year 2.77
Extreme 2.77
5.48
1 year 2.77
Extreme 2.77
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Corporate Officer/Principal 49 2008-08-10
Chief Executive Officer 59 2025-11-23
Director of Finance/CFO 53 2024-10-31
Director TitleAgeSince
Chairman 58 2020-11-24
Director/Board Member 56 2017-12-31
Director/Board Member 68 2021-05-24
Date Insider Type Main position Quantity % Market Cap. Importance
4/16/26 Other

Director

2,376 0.0006%
3/18/26 Other

Chief Financial Officer

645,750 0.1549%
3/18/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+0.66%-4.06%-47.97%-92.85% 25.6M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.48% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+27.04% 42.78B
+0.87%-8.17%+293.37%+643.87% 40.67B
+1.24%-1.01%+10.74%+94.55% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.60% 24.36B
Average +0.81%-2.80%+39.86%+89.94% 37.66B
Weighted average by Cap. +0.56%-2.94%+51.34%+114.83%

Financials

2026 *2027 *
Net sales - 4.67M 4.17M 3.88M 3.53M 6.66M 452M 6.68M 46.72M 18.28M 230M 17.53M 17.15M 739M
Net income -15.56M -13.89M -12.92M -11.75M -22.19M -1.51B -22.27M -156M -60.91M -768M -58.43M -57.15M -2.46B -11.81M -10.54M -9.81M -8.92M -16.84M -1.14B -16.91M -118M -46.24M -583M -44.35M -43.39M -1.87B
Net Debt - -
Projected Income Statement - Annual - Evaxion A/S
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
26-10-09 US$3.070 +0.66% 27,855
26-10-08 US$3.050 -3.48% 63,967
26-10-07 US$3.160 0.00% 21,750
26-10-06 US$3.160 +0.32% 35,874
26-10-05 US$3.150 -1.56% 38,242
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Evaxion A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.070USD
Average target price
11.25USD
Spread / Average Target
+266.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evaxion A/S
  1. Stock Market
  2. Stocks
  3. EVAX Stock